Ann: 2023 Annual Report to shareholders, page-190

If think that *if* an offer comes our way it will be considered thoughtfully by Jon and the board, based on what we have achieved at that time and what our future looks like. I am a firm believer that this exercise is about padding out our valuation, and that we'll either issue an exclusive license for 2591 (ex- Fragile X and Retts), or be taken over in a 'friendly' transaction. The comment from Jon saying that he wants an outcome that gets the treatment into the hands of the most patients as soon as possible is a win for both investors and patients alike. I think a forced takeover occurring (which is against the board's recommendations) is unlikely.

Right now it is still my feeling that we're 20%~ below a very conservative valuation on what we have right now, with no further success assumed so in my eyes it makes sense to stay the course and see what the next 6-12 months hold as the upside is large, and the downside is somewhat limited (pending something very left field) Daybue, PMS and our cash balance gives us a floor to our SP. That floor is lower than I thought but it is there, somewhere